Literature DB >> 35958444

Significance of intratreatment tumor volume change during chemoradiotherapy for potentially resectable thoracic esophageal squamous cell carcinoma.

Duojie Li1,2,3, Qun Zhang1,2,3, Yan Yang2,3, Hongmei Yin2,3, Chaomang Zhu2,3, Xianming Li1,4.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the clinical significance of tumor response assessment at a twentieth fraction of radiotherapy when predicting the survival of patients with potentially resectable esophageal squamous cell carcinoma (ESCC).
METHODS: A total of 123 ESCC patients with clinical stages II to IVa were enrolled and analyzed. Gross tumor volume (GTV) of the esophagus (GTVe) and GTV of the metastatic lymph node (GTVnd) were manually contoured by at least 2 senior professional radiotherapists on the simulated computed tomography (CT) images in a process that followed the delineating rules for ESCC.
RESULTS: The GTVe reduction ratio (RR) and GTVnd RR were calculated based on the evaluation of the tumor volume at a twentieth fraction of radiotherapy. Univariate analysis showed that GTVe and GTVnd before treatment, and GTVe RR and GTVnd RR at the twentieth fraction of radiotherapy were all significantly associated with complete clinical response (cCR) and overall survival (OS). The Kaplan-Meier method was used to estimate OS and locoregional recurrence-free survival (LRRFS).
CONCLUSIONS: The GTVe RR ≥27.92% and GTVnd RR ≥21.49% at a twentieth fraction of radiotherapy are positive predictive factors of LRRFS, and according to multivariate analysis, only GTVe RR at the twentieth fraction of radiotherapy ≥27.92% is prognostic for a favorable OS. AJTR
Copyright © 2022.

Entities:  

Keywords:  Esophageal neoplasms; computed tomography; definitive chemoradiotherapy; interim response; prognosis

Year:  2022        PMID: 35958444      PMCID: PMC9360855     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  25 in total

Review 1.  Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?

Authors:  Abraham J Wu; Karyn A Goodman
Journal:  J Gastrointest Oncol       Date:  2015-02

2.  Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.

Authors:  Drexell Hunter Boggs; Andrew Hanna; Whitney Burrows; Naomi Horiba; Mohan Suntharalingam
Journal:  J Gastrointest Cancer       Date:  2015-06

3.  Intratreatment Tumor Volume Change During Definitive Chemoradiotherapy is Predictive for Treatment Outcome of Patients with Esophageal Carcinoma.

Authors:  Ruihong Huang; Hong Guo; Jianzhou Chen; Tiantian Zhai; Junwei Chen; Kun Lin; Zhijian Chen; Derui Li; Chuangzhen Chen
Journal:  Cancer Manag Res       Date:  2020-08-18       Impact factor: 3.989

4.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

5.  Long-term outcomes and prognostic factors for patients with esophageal cancer following radiotherapy.

Authors:  Chuang-Zhen Chen; Jian-Zhou Chen; De-Rui Li; Zhi-Xiong Lin; Ming-Zhen Zhou; Dong-Sheng Li; Zhi-Jian Chen
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

7.  Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?

Authors:  F E M Voncken; H Jiang; J Kim; M Guindi; J Brierley; J Knox; G Liu; A M Horgan; J Lister; G Darling; U Metser; R K S Wong
Journal:  Dis Esophagus       Date:  2012-11-02       Impact factor: 3.429

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

9.  Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.

Authors:  Yun Chen; Jinjun Ye; Zhengfei Zhu; Weixin Zhao; Jialiang Zhou; Chaoyang Wu; Huarong Tang; Min Fan; Ling Li; Qin Lin; Yi Xia; Yunhai Li; Jiancheng Li; Huixun Jia; Saiquan Lu; Zhen Zhang; Kuaile Zhao
Journal:  J Clin Oncol       Date:  2019-03-28       Impact factor: 44.544

10.  Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Jun Gi Yeom; Jie-Hyun Kim; Jun Won Kim; Yeona Cho; Ik Jae Lee; Chang Geol Lee; Jaeyoung Chun; Young Hoon Youn; Hyojin Park
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.